These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26718579)

  • 1. D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia.
    Payer DE; Guttman M; Kish SJ; Tong J; Adams JR; Rusjan P; Houle S; Furukawa Y; Wilson AA; Boileau I
    Neurology; 2016 Jan; 86(3):224-30. PubMed ID: 26718579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comment: Increased D3 binding-A substrate for levodopa-induced dyskinesias?
    Stoessl AJ
    Neurology; 2016 Jan; 86(3):228. PubMed ID: 26718570
    [No Abstract]   [Full Text] [Related]  

  • 3. [¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders.
    Payer DE; Guttman M; Kish SJ; Tong J; Strafella A; Zack M; Adams JR; Rusjan P; Houle S; Furukawa Y; Wilson AA; Boileau I
    Mov Disord; 2015 Feb; 30(2):160-6. PubMed ID: 25641350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Preliminary Investigation of the Effect of Acute Alcohol on Dopamine Transmission as Assessed by [
    Thiruchselvam T; Wilson AA; Boileau I; Le Foll B
    Alcohol Clin Exp Res; 2017 Jun; 41(6):1112-1119. PubMed ID: 28421623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.
    Boileau I; Guttman M; Rusjan P; Adams JR; Houle S; Tong J; Hornykiewicz O; Furukawa Y; Wilson AA; Kapur S; Kish SJ
    Brain; 2009 May; 132(Pt 5):1366-75. PubMed ID: 19153147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo.
    Narendran R; Slifstein M; Guillin O; Hwang Y; Hwang DR; Scher E; Reeder S; Rabiner E; Laruelle M
    Synapse; 2006 Dec; 60(7):485-95. PubMed ID: 16952157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans.
    Graff-Guerrero A; Willeit M; Ginovart N; Mamo D; Mizrahi R; Rusjan P; Vitcu I; Seeman P; Wilson AA; Kapur S
    Hum Brain Mapp; 2008 Apr; 29(4):400-10. PubMed ID: 17497628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study.
    Boileau I; Payer D; Houle S; Behzadi A; Rusjan PM; Tong J; Wilkins D; Selby P; George TP; Zack M; Furukawa Y; McCluskey T; Wilson AA; Kish SJ
    J Neurosci; 2012 Jan; 32(4):1353-9. PubMed ID: 22279219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease.
    Hong JY; Oh JS; Lee I; Sunwoo MK; Ham JH; Lee JE; Sohn YH; Kim JS; Lee PH
    Neurology; 2014 May; 82(18):1597-604. PubMed ID: 24719485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925.
    Graff-Guerrero A; Redden L; Abi-Saab W; Katz DA; Houle S; Barsoum P; Bhathena A; Palaparthy R; Saltarelli MD; Kapur S
    Int J Neuropsychopharmacol; 2010 Apr; 13(3):273-87. PubMed ID: 19751545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of sigma-receptors in levodopa-induced dyskinesia in patients with advanced Parkinson disease: a positron emission tomography study.
    Nimura T; Ando T; Yamaguchi K; Nakajima T; Shirane R; Itoh M; Tominaga T
    J Neurosurg; 2004 Apr; 100(4):606-10. PubMed ID: 15070112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [
    Slifstein M; Abi-Dargham A; Girgis RR; Suckow RF; Cooper TB; Divgi CR; Sokoloff P; Leriche L; Carberry P; Oya S; Joseph SK; Guiraud M; Montagne A; Brunner V; Gaudoux F; Tonner F
    Psychopharmacology (Berl); 2020 Feb; 237(2):519-527. PubMed ID: 31773210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The D2/3 dopamine receptor in pathological gambling: a positron emission tomography study with [11C]-(+)-propyl-hexahydro-naphtho-oxazin and [11C]raclopride.
    Boileau I; Payer D; Chugani B; Lobo D; Behzadi A; Rusjan PM; Houle S; Wilson AA; Warsh J; Kish SJ; Zack M
    Addiction; 2013 May; 108(5):953-63. PubMed ID: 23167711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.
    Bézard E; Ferry S; Mach U; Stark H; Leriche L; Boraud T; Gross C; Sokoloff P
    Nat Med; 2003 Jun; 9(6):762-7. PubMed ID: 12740572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [(11)C]-(+)-PHNO.
    Caravaggio F; Nakajima S; Borlido C; Remington G; Gerretsen P; Wilson A; Houle S; Menon M; Mamo D; Graff-Guerrero A
    Neuropsychopharmacology; 2014 Nov; 39(12):2769-76. PubMed ID: 24874713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reward motivation in humans and its relationship to dopamine D
    Caravaggio F; Fervaha G; Browne CJ; Gerretsen P; Remington G; Graff-Guerrero A
    J Psychopharmacol; 2018 Mar; 32(3):357-366. PubMed ID: 29442593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [
    Schneier FR; Slifstein M; Whitton AE; Pizzagalli DA; Reinen J; McGrath PJ; Iosifescu DV; Abi-Dargham A
    Biol Psychiatry; 2018 Oct; 84(8):563-573. PubMed ID: 30041971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO.
    Tateno A; Sakayori T; Kim WC; Honjo K; Nakayama H; Arakawa R; Okubo Y
    Int J Neuropsychopharmacol; 2018 Jun; 21(6):522-527. PubMed ID: 29346639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease.
    Kaasinen V; Någren K; Hietala J; Oikonen V; Vilkman H; Farde L; Halldin C; Rinne JO
    Neurology; 2000 Apr; 54(7):1482-7. PubMed ID: 10751262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.